Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline Tuesday, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland, Ohio).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,